As patient advocates, we want to ensure that patient safety is a priority as FDA implements the Biologics Price Competition and Innovation Act (BPCIA). This message is especially timely given the recent news that FDA has accepted the first application for approval of a biosimilar... [W]e urge that all biologics, including biosimilars, carry distinguishable non-proprietary names
— IDF, AARDA, GHLF letter to FDA on Naming